Patients who experience disease progression within 36 months of starting quadruplet induction therapy and autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma may best be identified as having “functional high-risk” disease, according to a study published in Cancer. This 3-year benchmark replaces the historical 18-month standard, providing a more accurate framework for identifying patients who require intensive, immune-based second-line treatments to improve survival outcomes.
Redefining High-Risk Disease in the Quadruplet Era
The standard of care for newly diagnosed multiple myeloma has shifted significantly with the widespread adoption of quadruplet induction therapy—typically consisting of daratumumab, carfilzomib, lenalidomide, and dexamethasone—followed by ASCT. A multicenter retrospective analysis of 310 patients, led by Gayathri Ravi, MD, of the University of Alabama at Birmingham, found that the 18-month progression window no longer captures the full scope of high-risk disease in the modern treatment landscape.
Data from the study showed a cumulative incidence of progression at 2.6% within 12 months, 6.2% within 18 months, 10.1% within 24 months, and 16.4% within 36 months. By extending the definition to 36 months, clinicians can better identify patients who are likely to face poor outcomes with standard subsequent therapies. For those progressing within 12 months, the median overall survival (OS) was 8.1 months, while those progressing within 36 months saw an OS of 23.8 months.
Did you know?
The study utilized data from the phase 2 MASTER trial (NCT03224507), which evaluated response-adapted therapy using minimal residual disease (MRD) status to guide the duration of post-transplant treatment.
The Role of T-Cell–Redirecting Therapy
For patients identified as functional high-risk, the study highlights the importance of early intervention with T-cell–redirecting therapy (TCRT). Researchers compared outcomes for patients receiving TCRT—such as CAR T-cell therapy or bispecific antibodies—versus those who did not receive these agents after early progression.
The results indicated a substantial survival benefit for the TCRT cohort. According to the analysis, the overall response rate to second-line treatment was 91% for patients who received TCRT, compared with 47% for those who did not. Furthermore, the 1-year progression-free survival (PFS2) rate was 80% with TCRT, significantly higher than the 23% observed in the non-TCRT group. Ravi noted that these patients should be prioritized for immune-engaging treatments to achieve more durable cancer control.
Future Clinical Trial Implications
The shift to a 36-month benchmark is expected to influence the design of future clinical trials. By incorporating this updated definition of functional high-risk disease, researchers can better stratify patient populations and test the efficacy of novel agents earlier in the disease course.
The multicenter analysis provides a clear benchmark for investigators to assess whether new therapies can overcome the aggressive biology seen in patients who relapse within the first three years of initial quadruplet treatment. Moving forward, the focus remains on integrating these powerful immune therapies into earlier lines of treatment for those at the highest risk of rapid relapse.
Frequently Asked Questions
What is functional high-risk multiple myeloma?
It is a classification for patients who experience disease progression within a specific timeframe after initial intensive treatment. The current study suggests 36 months is the appropriate benchmark for patients treated with modern quadruplet therapy and ASCT.
Why is T-cell–redirecting therapy recommended for early relapsers?
TCRT, including CAR T-cell therapy and bispecific antibodies, has shown significantly higher response rates and improved survival compared to other second-line options for patients whose myeloma returns shortly after frontline treatment.
How does the 36-month definition compare to previous standards?
Historically, the benchmark for high-risk disease was 18 months. The study indicates that, with the efficacy of modern quadruplet regimens, an 18-month window is too narrow, and 36 months is a more accurate indicator of functional high-risk disease.
Are you a healthcare professional or a patient looking to stay informed on the latest developments in multiple myeloma treatment? Subscribe to our newsletter for the latest research updates and clinical trial news.
Worth a look